In 2019, the market for patient-controlled injectors was valued at approximately US$ 2,969.47 million and is anticipated to grow to US$ 7,505.70 million by 2027, reflecting a compound annual growth rate (CAGR) of 12.4% from 2020 to 2027.
The expansion of the patient-controlled injectors market can be primarily linked to the rising incidence of chronic illnesses and an increase in patient adherence to treatment regimens. Nevertheless, the slow adoption of these devices in developing nations may hinder market growth during the projected period.
The demand for patient-controlled injectors is expected to increase due to their enhanced convenience, safety, and comfort in administering injections, making them increasingly popular among patients. Furthermore, these injectors allow patients to self-administer their medication and control their dosage, which is a significant advantage.
Moreover, patient-controlled injectors can be utilized in home environments, leading to a surge in their demand. They provide an effective solution for administering larger doses in non-clinical settings. A significant number of these injectors are employed for subcutaneous drug delivery in home care scenarios. Variants of these self-administration devices are specifically designed to handle highly viscous medications in substantial volumes. According to the World Health Organization (WHO), around 2 million healthcare professionals face percutaneous exposure to infectious diseases annually. The data indicates that 37.6% of Hepatitis B and 4.4% of HIV/AIDS infections among healthcare workers are attributed to needle stick injuries globally. In response, many manufacturers are concentrating on developing patient-controlled injectors to address these unmet needs, thereby propelling market growth. The straightforward administration of these medications is vital for enhancing patient compliance with drug therapies, which ultimately improves patient outcomes. Given these considerations, there is a growing preference for controlled injectors, such as self-dose devices and Tremfya, among both patients and healthcare providers. Additionally, these self-injectors are regarded as safe and effective. For example, a clinical trial report from July 2019 indicated that Guselkumab, delivered via a one-press patient-controlled injector, was highly effective and well-tolerated in patients with moderate-to-severe psoriasis. The researchers concluded that the one-press controlled injector was significantly more acceptable than traditional drug delivery methods. Unlike other routes of drug administration, this innovative method does not necessitate stringent sterile techniques for drug delivery into the body. Consequently, the increasing awareness of the benefits of patient-controlled injectors among patients and healthcare professionals is driving market growth.
The demand for patient-controlled injectors saw a notable increase during the pandemic. Factors such as a growing patient population, limited healthcare resources, and the convenience of these injectors contributed positively to market adoption. However, the implementation of physical distancing measures and the complete shutdown of businesses to curb viral transmission disrupted supply chain operations, negatively affecting market growth.
The patient-controlled injectors market is categorized by product type into electronic wearable injectors, mechanical wearable injectors, and infusion pumps. In 2019, the electronic wearable segment dominated the market share, while the mechanical wearable injector segment is expected to exhibit the highest CAGR during the forecast period.
In terms of application, the market is divided into segments for cancer treatment, autoimmune treatment, blood disorder treatment, and others. The cancer treatment segment held the largest market share in 2019 and is projected to experience the fastest growth in the coming years.
Regarding distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and mail-order pharmacies. The hospital pharmacies segment accounted for the largest share in 2019 and is expected to show the fastest growth during the forecast period.
Key sources for this report include major organizations such as the World Health Organization (WHO), the Food and Drug Administration (FDA), the National Health Service (NHS), and the Centers for Disease Control and Prevention (CDC).